Compare Biogen Inc (BIIB) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares Self-Driving EV and Tech — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while iShares Self-Driving EV and Tech trades at $37.18. The key difference: Biogen Inc is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| BIIB | IDRV | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.63 | $45.48 |
52-Week Low | $132.22 | $34.49 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
IDRV trades at $37.24, down 0.35% on the day, with a bullish technical signal driven by moving averages. The stock is positioned near its pivot point of $37, with key resistance at $38 and support at $36. Recent news highlights strong global EV sales growth and China's ambitious 2030 fleet target, supporting the thematic focus of the fund.
The outlook for IDRV is supported by positive industry trends in electric vehicles, though the absence of key valuation and profitability ratios limits fundamental assessment. Risks include competitive pressures and regulatory changes, while analyst sentiment is mixed with a slight bullish bias. The stock's performance remains tied to broader EV market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →
